Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma

NCT04458272 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT04458272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 8, 2020
Completion date
February 28, 2027
Enrollment
25 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

who grade ii glioma